

1 SUPPORTING INFORMATION

2

3 MATERIALS AND METHODS

4 **Cell culture.** Primary normal human bronchial epithelial cells (NHBE, Lonza) from genetically
5 independent donors were grown as monolayers from low passages in serum-free pre-defined
6 bronchial epithelial cell growth medium according to manufacturer's instructions (BEGM
7 BulletKit, Lonza). NHBEs were treated in 12-well plates at 80% confluence. To avoid effects
8 induced by growth factors in the BEGM medium, cells were rested in basal medium without
9 supplements for 12 hours, then stimulated with icatibant at 1 nM or hydrocortisone at 10 µM,
10 followed by further 24 hours of infection with SARS-CoV-2 at the biosafety level 3 laboratory.
11 For RNA analysis, cells were lysed in RLT buffer (Qiagen, Hilden, Germany). For protein
12 analysis, cells were lysed in 1x protein extraction buffer provided with the ACE2 ELISA Kit
13 (Abcam, Cambridge, UK). Cell culture supernatant was collected for further viral and cytolytic
14 analysis.

15

16 **Infection with SARS-CoV-2.** The SARS-CoV-2 isolate hCoV-19/Germany/BAV-PL-
17 virotum-nacq/2020 (GISAID accession ID: EPI_ISL_582134) was derived from patient
18 material and amplified on Vero E6 cells (passage 0; ATCC, Manassas, US) and used for
19 infection experiments (passage 4) with an MOI of 0.5 (determined by plaque assay) by adding
20 virus stock to the BEBM culture medium after 24 hours of stimulation. Time of harvest after
21 inoculation was dependent on the experimental setting. For repetitive treatment with icatibant
22 of NHBEs post-infection (Fig.2D-I), NHBEs from 8 genetically independent donors were
23 infected with SARS-CoV-2 with a MOI of 0.5 at T-6 and after 6 hours (T0), treatment with a
24 range of doses of icatibant was started and repeated every 24 hours. Cells were harvested at 24,
25 48, 72 and 96 hours after treatment start and subjected to RNA extraction and relative viral
26 RNA quantification normalized to a housekeeper index.

27

28 **Plaque assay.** Supernatant of SARS-CoV-2-infected NHBEs was titrated (1:5 dilutions of the
29 stock) in Dulbecco's Modified Eagle Medium (DMEM) with 1% penicillin / streptomycin, 1%
30 L-glutamine, 1% non-essential aminoacids, and 1% sodium pyruvate (all Gibco, Thermo Fisher
31 Scientific, Carlsbad, CA, USA) in a total volume/well of 100 μ l on 96-well plates containing
32 70-80 % confluent Vero E6 cells. After 2 hours, the inoculum was discarded, and cells were
33 layered with 100 μ l MEM containing 0.5 % carboxymethyl cellulose (1,500 cP, Sigma-Aldrich,
34 St. Louis US). 48 hours post inoculation, 100 μ l formaldehyde was added to a final
35 concentration of 5 % for 15 min. Supernatant was taken off, cells were washed with PBS twice
36 and incubated with crystal violet (Sigma-Aldrich) solution for 15 min and washed with PBS
37 again. Plaque-forming units per milliliter pfu/ml were calculated with the formula $\text{pfu/mL} =$
38 number of plaques/dilution x volume of analyzed supernatant.

39

40 **RNA isolation and gene expression analysis.** mRNA was extracted from patient nasal
41 brushings and from NHBEs using RNeasy Micro Kit (Qiagen) with on-column DNase digestion
42 (Qiagen). RNA quantification and quality assessment were performed using Nanodrop
43 Technologies (Wilmington) and RNA 6000 Nano Chip Kit with the Agilent 2100 Bioanalyzer
44 (Agilent Technologies, Waldbronn, Germany) according to manufacturer's instructions.

45

46 **RT-qPCR-based detection of SARS-CoV-2 RNA.** Isolated RNA was subject to cDNA
47 synthesis by SuperScript III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen). On a
48 LightCycler 480 II (Roche Diagnostics, Penzberg, Germany) total SARS-CoV-2 RNA was
49 quantified using SARS-CoV-2 N1 primers and probe according to CDC guidelines and a SYBR
50 Green PCR mix (Roche Diagnostics). SARS-CoV-2 genomic RNA was quantified using RdRP
51 primers. The specific primers used in real-time PCR are listed in Table S21. SARS-CoV-2 RNA
52 was normalized with relative quantification to endogenous control ACTB using the $1/ECT$

53 formula.

54

55 **3D-bronchial air-liquid interphase organoid cultures.** Low passage primary NHBEs were
56 expanded to 95% confluence in PneumaCult-Ex Plus expansion medium (Stemcell) according
57 to manufacturer's instructions. Corning transwell polyester membrane cell culture inserts (type
58 3460, Merck) were precoated with 1% collagen (Sigma-Aldrich) and the cells were transferred
59 to 12-well plates containing precoated transwell inserts on day 0 with a density of 3×10^5
60 cells/cm². Every other day, PneumaCult-Ex Plus expansion medium (Stemcell) was replenished
61 in apical and basal chambers. On day 3, cells were lifted to air (air-lift) by removing the apical
62 medium. Medium in the basal chamber was exchanged for Pneumacult-ALI maintenance
63 medium (Stemcell). Excess mucus was removed from day 7. Once a week, the transepithelial
64 electrical resistance (TEER) was measured using an EVOM2 instrument (World Precision
65 Instruments). With a TEER of >700, but from day 21 at the earliest, the 3D organoid cultures
66 were regarded as completely differentiated and were then treated and infected with SARS-CoV-
67 2.

68

69 **Infection of 3D organoid cultures.**

70 24 hours prior to treatment of the 3D air-liquid interphase organoid cultures, the supplement
71 hydrocortisone was withdrawn. The cultures were then pretreated from the basal side
72 with/without 1 nM icatibant (HOE 140 (icatibant), Sigma-Aldrich) for 24 hours. Subsequently,
73 SARS-CoV-2 viral suspension (MOI 0.5, strain hCoV-19/Germany/BAV-PL-virotum-
74 nacq/2020) was added from the apical side and incubated for 2 hours, then the virus suspension
75 was removed with PBS washes and the cultures were kept for another 46 hours before harvest.

76

77 **FFPE sections of 3D organoid cultures.** Cultures were fixed in 4% paraformaldehyde and
78 embedded in paraffin and sections of 4 μm thickness were produced at the routine diagnostics

79 at the Medical School of the Technical University of Munich, Campus Biederstein. Slides were
80 subjected to standard hematoxylin eosin staining to identify the culture structure by light
81 microscopy.

82

83 **Tissue homogenization and murine ACE2 ELISA.** Tissue lysates were prepared by
84 homogenization in ice-cold lysis buffer (Cell Signaling) to a final concentration of 2x lysis
85 buffer in water, containing protease inhibitor (Complete Mini, Roche). 0.1 ml of lysis buffer
86 was added per 100 mg of tissue. Tissue was homogenized using metal beads and Qiagen tissue
87 lyser 20/s for 90 seconds until it was completely homogenized. Samples were centrifuged for
88 10 minutes at 11,000 x g at 4°C and supernatants were transferred to fresh tubes. Total protein
89 concentration was determined with the Pierce BCA Protein Assay Kit (Thermo Scientific) to
90 determine extraction efficacy across samples, before further analysis by ELISA. Mouse ACE2
91 ELISA (PicoKine Kit, Boster Bio) was performed according to the manufacturer's instructions
92 using tissue lysate diluted 1:100. Colorimetric readout was acquired using Spark microplate
93 reader (Tecan). Data analysis was performed using Microsoft Excel, R and GraphPad Prism.

94

95 **Reverse transcription and quantitative real-time qPCR.** Isolated total RNA was reverse
96 transcribed using a high-capacity cDNA kit (Applied Biosystems) according to manufacturer's
97 instructions. Real-time PCR profiles were visualized using FastStart Universal SYBR Green
98 Mastermix (Roche) and quantified by the ViiA 7 Real-Time PCR System (Applied
99 Biosystems). The specific primers used in real-time PCR are listed in supplementary Table S21.
100 ACE2 and TMPRSS2 mRNA expression was normalized to housekeeping gene index *ACTB*
101 and *HPRT* and the relative quantification was performed using the comparative threshold cycle
102 ($2^{-\Delta\Delta C_t}$) method (relative gene expression). All amplifications were carried out at least in
103 duplicate.

104

105 **Gene expression analysis using Agilent microarray technologies.** Microarray experiments
106 were performed using MIAME criteria. Genespring Software GX 14.9.1 (Agilent
107 Technologies) with minimal data reduction constraints (1.5-fold change and $P < 0.05$ cutoff) was
108 used to analyze microarray data as previously described.^{1,2} Upon data import a standard
109 baseline transformation to the median of all values was performed, including log transformation
110 and computation of fold changes ($\log_2(A/B) = \log_2(A) - \log_2(B)$). Subsequently, a principle
111 component analysis was conducted, which revealed a homogenous component distribution.
112 Compromised array signals were excluded from further analysis (array spot is non-uniform if
113 pixel noise of feature exceeds threshold or is above saturation threshold). Genes with an
114 absolute \log_2 fold change larger than 1.5 and a p-value smaller than the testing level of 0.05 by
115 using the Moderated T-Test were defined as significantly differentially expressed hits. The
116 significantly regulated genes were summarized in entity lists (see supplemental tables). These
117 entity lists were analyzed for overlaps using Venn diagrams. Manhattan cityblock on entities
118 (Ward's linkage) was used to cluster changes in gene expression.

119 Gene Ontology (GO) terms "0007267", "0005125", "0008009", and "0005615" for secreted
120 factors, GO terms "0007267", "0005125", "0008009", and "0005615" for identification of
121 biomarkers, GO terms "0038023", "0004896", "0004888", and "0005887" for surface receptors,
122 GO terms "0009615", "0039528", "0039530", "0039639", "0051607", and "0009597" for anti-
123 viral response. Membrane-bound cell surface receptors were selected from a Venn diagram
124 analysis of the GO-term selection of surface receptors (see above) minus the GO-term selection
125 of secreted genes (see above) in order to isolate surface receptors that are not as well secreted
126 as soluble ligands. The data discussed in this publication will be deposited in NCBI's Gene
127 Expression Omnibus and are accessible through GEO Series accession number pending.

128

129 **String network analysis.** Protein-protein interactions were computed using an open-access
130 tool, the string network analysis version 11.0 (string-db.org)³⁻¹³ in order to extract enriched

131 cellular processes and pathways affected by icatibant treatment. The classical classification
132 systems Gene Ontology was relevant for this study. Enriched entities are colored in the
133 interaction plots: violet for GO:0007186 “G protein-coupled receptor signaling pathway” and
134 light green for GO:0006811 “Ion transport” in Figure 2.

135

136 **Cytotoxicity assay.** Lactate Dehydrogenase Assay (LDH) assay for assessing the cytotoxicity
137 of virus-infected NHBES in combination with or without icatibant was performed using the
138 LDH-detecting CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega GmbH)
139 according to manufacturer’s instructions.

140

141 **ELISA for human ACE2 levels.** Protein levels of ACE2 in NHBE cell lysates were determined
142 using the human ACE2 ELISA Kit (Abcam). Assays were performed according to
143 manufacturer’s instructions.

144

145 **Statistical analysis.** Two-tailed Mann-Whitney U tests were used to determine statistical
146 significance (GraphPad Prism Version 8.4.2, GraphPad Software). For the in vivo mouse study,
147 we performed a prospective power analysis based on human data that predict a 33% reduction
148 in ACE2 following icatibant treatment (mean 1: 1; mean 2: 0.666; SD: 0.26; alpha = 0.05; P =
149 0.9, power.t.test in R, rounded up). In accordance with the criteria of this *a priori* power
150 analysis, we used a 1-tailed t-test, that compared icatibant-treated groups with untreated groups,
151 resulting in 12 animals per group. Here, we have specifically tested the hypothesis for a
152 downregulation of ACE2 only in mice treated with icatibant compared to untreated mice. The
153 half maximal inhibitory concentration (IC₅₀) values were deferred from sigmoidal interpolation
154 of a standard curve using a robust nonlinear regression model in GraphPad Prism. Results are
155 depicted as median with range, if not otherwise indicated in the figure legends. P<0.05 was
156 considered statistically significant. Statistically significant differences were depicted as p-

157 values *P<0.05, **P<0.01, and ***P<0.001.

158

159 **Data availability statement.** The data discussed in this publication are deposited in NCBI's

160 Gene Expression Omnibus and are accessible under the GEO Series accession number

161 GSE176405.

162

163 SUPPLEMENTAL TABLES

164 Table S1. DEGs from transcriptome analysis filtered on secreted factors from nasal scrapings
165 from SARS-CoV-2 acute positive patients compared to negative patients

166 Table S2. DEGs from transcriptome analysis filtered on kallikreins from nasal scrapings from
167 SARS-CoV-2 acute positive patients compared to negative patients

168 Table S3. DEGs from transcriptome analysis filtered on kinin-kallikrein-system members from
169 nasal scrapings from SARS-CoV-2 acute positive patients compared to negative patients

170 Table S4. DEGs comparing SARS-CoV-2 + B2R antagonist versus SARS-CoV-2

171 Table S5. DEGs comparing SARS-CoV-2 + hydrocortisone (HC) versus SARS-CoV-2

172 Table S6. DEGs of antiviral epithelial response comparing SARS-CoV-2 versus medium

173 Table S7. DEGs of antiviral epithelial response comparing SARS-CoV-2 versus medium

174 Table S8. Gene expression of members of the acute-phase response comparing SARS-CoV-2
175 versus medium

176 Table S9. Gene expression of members of RAS and KKS comparing SARS-CoV-2 versus
177 medium

178 Table S10. Differentially expressed interleukins comparing SARS-CoV-2 versus medium

179 Table S11. Potential viral entry receptor DEGs comparing SARS-CoV-2 versus medium

180 Table S12. Toll-like receptor (TLR) DEGs comparing SARS-CoV-2 versus medium

181 Table S13. Chemokine DEGs comparing SARS-CoV-2 versus medium

182 Table S14. Gene expression of potential viral entry receptors comparing SARS-CoV-2 versus
183 medium

184 Table S15. Membrane-bound receptor DEGs comparing SARS-CoV-2 + B2R antagonist versus
185 SARS-CoV-2

186 Table S16. Membrane-bound receptor DEGs comparing SARS-CoV-2 + B2R antagonist versus
187 SARS-CoV-2 ($P \leq 0.05$; $FC \geq 2.5$)

188 Table S17. Interactions output of String network analysis of membrane-bound receptor DEGs
189 comparing SARS-CoV-2 + B2R antagonist versus SARS-CoV-2

190 Table S18. Cellular process enrichment analysis output of String network analysis of
191 membrane-bound receptor DEGs comparing SARS-CoV-2 + B2R antagonist versus SARS-
192 CoV-2

193 Table S19. Membrane-bound cell surface receptor DEGs, upregulated in SARS-CoV-2 versus
194 medium

195 Table S20. Cut set: Membrane-bound cell surface receptor DEGs, upregulated in SARS-CoV-
196 2 versus medium and downregulated in SARS-CoV-2 + B2R antagonist versus SARS-CoV-2

197 Table S21. Reagents

198

199 SUPPLEMENTAL FIGURE LEGENDS

200 Figure S1. Epithelial response of primary NHBEs to SARS-CoV-2 infection.

201 Gene expression analysis of NHBEs after 24 hours of SARS-CoV-2 infection versus medium
202 using microarray technology: A) Heat map of selected genes of the KKS and RAS are depicted
203 independent of significance analysis. All entities are shown. Asterisks indicate significantly
204 regulated genes ($P < 0.05$) in SARS-CoV-2 compared to medium. Heat map of gene expression
205 analysis of B) epithelium-derived interleukins, C) a selection of confirmed and potential SARS-
206 CoV-2 entry receptors, D) Toll-like family members, E) factors involved in the immediate
207 antiviral response of infected epithelial cells, and of E) chemokines. In B-F, only significantly
208 regulated entities in SARS-CoV-2-infected versus uninfected NHBEs are shown. Color code
209 indicates Log₂-fold change from low (blue) through 0 (white) to high (red). Duplicate gene
210 names indicate the abundance of two or more isoforms of the same gene in the analysis.

211

212 Figure S2.

213 A) Analysis of *TMPRSS2* gene expression by qPCR after 24 hours of pre-treatment of NHBES
214 of 10 donors with/without 1 nM B₂R antagonist, followed by SARS-CoV-2 inoculation for 24
215 hours of NHBES. Results are depicted as median with range. B) *ACE2* gene expression analysis
216 using qPCR after 24 hours of pre-treatment with/without 10 μM hydrocortisone (HC) followed
217 by 24 hours of SARS-CoV-2 infection of NHBES. Results are depicted as median with range.
218 For Figures S2A and B, statistical tests compared SARS-CoV-2-infected versus uninfected
219 samples or B₂R antagonist-treated versus untreated samples. C) Heat map of gene expression
220 analysis of membrane-bound cell surface receptors included in pathway analysis in Figures
221 4A,B, the were the highest downregulated upon pre-treatment with B₂R antagonist during
222 SARS-CoV-2 infection of NHBES are depicted. SARS-CoV-2 + B₂R antagonist and SARS-
223 CoV-2 are shown (FC≥2.5; P≤0.05). Color code indicates Log₂-fold change from low (blue)
224 through 0 (white) to high (red). Duplicate gene names indicate the abundance of two or more
225 isoforms of the same gene in the analysis.
226
227

- 229 1. Zissler UM, Chaker AM, Effner R, et al. Interleukin-4 and interferon-gamma
230 orchestrate an epithelial polarization in the airways. *Mucosal Immunol.* 2016;9(4):917-
231 926.
- 232 2. Zissler UM, Jakwerth CA, Guerth FM, et al. Early IL-10 producing B-cells and
233 coinciding Th/Tr17 shifts during three year grass-pollen AIT. *EBioMedicine.*
234 2018;36:475-488.
- 235 3. Franceschini A, Lin J, von Mering C, Jensen LJ. SVD-phy: improved prediction of
236 protein functional associations through singular value decomposition of phylogenetic
237 profiles. *Bioinformatics.* 2016;32(7):1085-1087.
- 238 4. Franceschini A, Szklarczyk D, Frankild S, et al. STRING v9.1: protein-protein
239 interaction networks, with increased coverage and integration. *Nucleic Acids Res.*
240 2013;41(Database issue):D808-815.
- 241 5. Jensen LJ, Kuhn M, Stark M, et al. STRING 8--a global view on proteins and their
242 functional interactions in 630 organisms. *Nucleic Acids Res.* 2009;37(Database
243 issue):D412-416.
- 244 6. Snel B, Lehmann G, Bork P, Huynen MA. STRING: a web-server to retrieve and
245 display the repeatedly occurring neighbourhood of a gene. *Nucleic Acids Res.*
246 2000;28(18):3442-3444.
- 247 7. Szklarczyk D, Franceschini A, Kuhn M, et al. The STRING database in 2011: functional
248 interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res.*
249 2011;39(Database issue):D561-568.
- 250 8. Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction
251 networks, integrated over the tree of life. *Nucleic Acids Res.* 2015;43(Database
252 issue):D447-452.
- 253 9. Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association
254 networks with increased coverage, supporting functional discovery in genome-wide
255 experimental datasets. *Nucleic Acids Res.* 2019;47(D1):D607-D613.
- 256 10. Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-
257 controlled protein-protein association networks, made broadly accessible. *Nucleic Acids*
258 *Res.* 2017;45(D1):D362-D368.
- 259 11. von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database
260 of predicted functional associations between proteins. *Nucleic Acids Res.*
261 2003;31(1):258-261.
- 262 12. von Mering C, Jensen LJ, Kuhn M, et al. STRING 7--recent developments in the
263 integration and prediction of protein interactions. *Nucleic Acids Res.* 2007;35(Database
264 issue):D358-362.
- 265 13. von Mering C, Jensen LJ, Snel B, et al. STRING: known and predicted protein-protein
266 associations, integrated and transferred across organisms. *Nucleic Acids Res.*
267 2005;33(Database issue):D433-437.
- 268